Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ceftolozane-tazobactam

ceftolozane-tazobactam

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of ceftolozane-tazobactam

8 trials tracked of ceftolozane-tazobactam: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 149 citations.

8Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 3 Phase 1 2
  1. Phase 3 Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) Completed · 149 cited
  2. Phase 4 Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Completed · 49 cited
  3. Phase 3 Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) Completed · 18 cited
  4. Phase 2 MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) Completed
  5. Phase 2 MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034) Completed
  6. Phase 2 Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid Completed
Show 2 more trials
  1. Phase 1 Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036) Completed
  2. Phase 1 Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds no mortality difference between CA and CT for drug-resistant P. aeruginosa infections
Infectious Disease Meta-analysis
Meta-analysis finds no mortality difference between CA and CT for drug-resistant P. aeruginosa infections Which antibiotic works better for dangerous drug-resistant infections?
A meta-analysis of 10 observational studies including 1409 patients with drug-resistant P.
Two powerful new antibiotics show equal survival rates for patients fighting dangerous, drug-resistant infections.
Apr 2, 2026